

**Remarks**

Claims 1-31 are pending in the application, of which claims 16-31 have been withdrawn.

Claims 1, 6 and 11 have been amended and remain supported by the originally filed claims and the specification at, for example, pages 4-5 at ¶¶ 6, 9; page 9 at ¶ 20.

The term "hypovolemia" has been deleted from claims 1, 6, and 11 because it has the same meaning as the term "shock" as described in the specification at, for example, page 4 at ¶ 9; and page 9 at ¶ 20.

No issues of new matter should arise and entry of the amendment is respectfully requested.

**Rejection under 35 USC § 102**

Claims 1-15 are rejected under 35 USC § 102(b) as anticipated by Elan Pharma's Zonisamide FDA Approved Labeling Text (March 27, 2000). Applicants respectfully traverse.


The cited reference does not disclose or suggest informing a patient that pancreatitis is a potential adverse event associated with zonisamide treatment and does not disclose or suggest what the symptoms of pancreatitis are.

Response Under 37 CFR § 1.111  
US Application No. 10/644,935  
Page 8 of 8

**Summary**

Applicant respectfully requests an early and favorable reconsideration and allowance of claims 1-15. The Examiner is encouraged to contact the undersigned to expedite prosecution of this application.

Respectfully submitted,



Thomas Wiseman  
Registration No. 35,046

Edward D. Grieff  
Registration No. 38,898

Date: 5/14/07

Venable LLP  
575 7th Street, NW  
Washington, DC 20004  
Phone: 202-344-4382  
Fax: 202-344-8300